Physician profile
Ariel Meyer
NPI 1083887129
$4,489.52
in general payments reported to CMS, 2019-2025
33 companies · $1,391 in 2025
The $1,391 reported for 2025 was more than what 85% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $808 · 2020: $355 · 2021: $425 · 2022: $612 · 2023: $205 · 2024: $693 · 2025: $1,391.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238 · Education: $51.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,237.70 |
| Education | $51.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $660.26 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $436.85 | 2019-2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $297.91 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $243.83 | 2019-2025 | Jynarque, Voyxact |
| Ardelyx, INC. | $240.52 | 2023-2025 | Xphozah 30 Mg, Ibsrela |
| Amgen INC. | $209.41 | 2022-2025 | Tavneos, Parsabiv, Krystexxa |
| Calliditas Therapeutics US INC. | $202.98 | 2023-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $201.53 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $190.22 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $175.33 | 2019-2024 | Velphoro |
| Ani Pharmaceuticals, INC. | $161.16 | 2024-2025 | Purified Cortrophin Gel |
| Daiichi Sankyo INC. | $156.40 | 2019-2025 | Injectafer |
| Mallinckrodt Hospital Products INC. | $150.60 | 2020-2024 | Terlivaz |
| Novo Nordisk INC | $145.43 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Smith+Nephew, INC. | $131.94 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $127.61 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.40 | 2021-2025 | |
| Akebia Therapeutics INC | $110.69 | 2019-2025 | Vafseo |
| Glaxosmithkline, LLC. | $110.05 | 2022-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $102.73 | 2019-2025 | |
| Horizon Therapeutics Plc | $52.79 | 2019-2021 | |
| Scpharmaceuticals INC. | $36.93 | 2025 | |
| Lilly USA, LLC | $36.13 | 2024-2025 | Jardiance |
| Apellis Pharmaceuticals, INC. | $34.11 | 2025 | Empaveli |
| Pharmacosmos Therapeutics INC. | $30.92 | 2021 | |
| Octapharma USA, INC. | $24.96 | 2019 | |
| Travere Therapeutics, INC. | $17.92 | 2025 | |
| Boston Scientific Corporation | $17.50 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.00 | 2020 | |
| Alnylam Pharmaceuticals INC. | $14.92 | 2021 | |
| Strongbridge US INC. | $14.16 | 2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.60 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ariel Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.